Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Up 1.5% – Still a Buy?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price rose 1.5% on Wednesday . The company traded as high as $1.99 and last traded at $1.97. Approximately 33,256 shares traded hands during trading, an increase of 17% from the average daily volume of 28,545 shares. The stock had previously closed at $1.94.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Friday, October 31st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

Kiora Pharmaceuticals Trading Up 1.5%

The stock has a 50-day moving average price of $2.13 and a two-hundred day moving average price of $2.55. The stock has a market cap of $7.25 million, a price-to-earnings ratio of -0.94 and a beta of -0.89.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, November 7th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.73. Research analysts predict that Kiora Pharmaceuticals, Inc. will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Two Sigma Investments LP purchased a new position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,984 shares of the company’s stock, valued at approximately $33,000. Two Sigma Investments LP owned about 0.33% of Kiora Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.